KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Net Margin (2016 - 2025)

Regeneron Pharmaceuticals has reported Net Margin over the past 17 years, most recently at 21.74% for Q4 2025.

  • Quarterly results put Net Margin at 21.74% for Q4 2025, down 247.0% from a year ago — trailing twelve months through Dec 2025 was 31.41% (up 34.0% YoY), and the annual figure for FY2025 was 31.41%, up 34.0%.
  • Net Margin for Q4 2025 was 21.74% at Regeneron Pharmaceuticals, down from 38.89% in the prior quarter.
  • Over the last five years, Net Margin for REGN hit a ceiling of 1947.0% in Q1 2022 and a floor of 21.74% in Q4 2025.
  • Median Net Margin over the past 5 years was 36.95% (2025), compared with a mean of 312.08%.
  • Biggest five-year swings in Net Margin: surged 190290bps in 2022 and later crashed -192114bps in 2023.
  • Regeneron Pharmaceuticals' Net Margin stood at 1857.5% in 2021, then fell by -1bps to 1841.69% in 2022, then tumbled by -98bps to 33.77% in 2023, then decreased by -28bps to 24.22% in 2024, then fell by -10bps to 21.74% in 2025.
  • The last three reported values for Net Margin were 21.74% (Q4 2025), 38.89% (Q3 2025), and 37.86% (Q2 2025) per Business Quant data.